

REFERENCES

- 01 Atherdn LM, Edt, Bentley and Drivers, "Text Book of Pharmaceutical Chemistry" 8th Edn., *Oxford University press*, 1996.
- 02 Wolff ME, Edt, "Burger's Medicinal Chemistry", Part IV, 4th Edn., *Wiley Inter Science*, New York, 1981.
- 03 Deorge RF, Edt, "Wilson and Gisvold's text book of Organic and Medicinal and Pharmaceutical Chemistry", 9th Edn., *Lippincott Company*, 1991.
- 04 Korolkovas A., "Essentials of Medical Chemistry"., 2nd Edn, *Wiley Inter Science*, New York, 1998.
- 05 Goodman LS and Gilman AG., "The Pharmacological basis of therapeutics", 9th Edn, *Mc. Graw-Hill*, 1996.
- 06 William O Foye, Edt, "Principles of Medicinal Chemistry", 3rd Edn, *Varghese*, Bombay, 1989.
- 07 Melentyeva G., Antynova L., "Pharmaceutical Chemistry"., *Mir Publishers*, Moscow, 1988.
- 08 Alfonso RG., "Remington's Pharmaceutical Sciences", 18th Edn, *Mack publishing company*, Pennsylvania, 1990.
- 09 Vega JA, Mortimer AM, Tson PJ, "*The Journal of clinical psychiatry*"., 64(5), 2003, 568- 574.
- 10 David N Havely, Editor Merck &Harp and Dohme Research Laboratory, The "*Merck Manual*, XII Edition", 1878, 1975.
- 11 John E Hoover., Managing Editor, Mark Publishing Co, Easton, PA, U.S.A., "*Remington's Pharmaceutical Science*, 15th Edition"., 887,1975.
- 12 Peses M and Bartos, "*J.Am.Pharm*"., France, 20,60, 1962. "*J.Pharm.Sci*", 57, 1231, 1968.
- 13 "*Guide lines for submitting Samples and Analytical Data for Methods Validation*", US Food and Drug Administration, Center for Drugs and Biologics, Department of Health and Human Sciences, 1987.

References

- 14 Dale Martin, Reynolds JFK; The extra Pharmacopia, 32nd Edition, Royal Pharmaceutical Press, London, 1998.
- 15 Lippocott Williams, Wilkins; The Science and Practice of Pharmacy, Volume 1 and 2, 19th Edition, New York, 1995.
- 16 Deorge RF, Edt, Wilson and Gisvolds "Text book of organic and medicinal and pharmaceutical Chemistry"., 8th Edn, *Lippincott Company*, 1982.
- 17 Erni F and Helboe P, "*Pharma times*"., 10,9, 1996.
- 18 "*The Drugs and Cosmetics Act and Rules*, Government of India publications, 1984.
- 19 "*Pharmacopoeia of India*", Ministry of Health and Family welfare, Controller of publications, Delhi, Vol. 1&2, 1996.
- 20 "*United States Pharmacopoeia*" USP 24., USP Convention Inc. Rockville, 2000.
- 21 "*European Pharmacopoeia*"., 3rd Edn, Council of Europe, Strasbourg, 1997 (supplement 1999).
- 22 "*British Pharmacopoeia*", HMSO, London, CD-ROM , 2000.
- 23 The complete drug reference, "*Martindale Extra Pharmacopoeia*", 33rd Edn, The Pharmaceutical press, London, 2002.
- 24 "*The Merck Index*", 13th Edn, Merck & Co. Inc., New York, 2001.
- 25 ICH guidelines, impurities in new drug substances, Q3A (R2), October 25, 2006.
- 26 Rentsch KM., Journal of biochemical and biophysical methods, 54, (1-3), 2002, 1-9.
- 27 Ahuja S, Alsante KM.; Separation science and technology, academic press, 5, 2003.
- 28 Ahuja S; Impurities evaluation of pharmaceuticals, marcel dekker, Inc. New York, 2006.
- 29 Ahuja S, Scypinski S; separation science and technology, academic press, 2003.
- 30 Roy J; Journal of the american association of pharmaceutical scientists tech, 3(2), 2002, 1-8.

References

- 31 ICH Harmonized triplicate guideline: impurities in new drug substances, step 4 of ICH process, 25th Oct. 2006.
- 32 ICH Harmonized triplicate guideline: impurities in new drug products Q3B (R2), ICH steering committee, step 4 of ICH process, 2nd June 2006.
- 33 ICH Harmonized triplicate guideline: guideline for residual solvents Q3C (R3), ICH steering committee, step 4 of ICH process, Nov 2005.
- 34 Gorog S, Babjak M, Balogh G; *Talanta*, 44, (1997) 1517-1526.
- 35 US pharmacopeia 29/national formulary 24, 1086, Rockville, MD, (2006) 2921.
- 36 International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH S6: preclinical safety evaluation of biotechnology-derived pharmaceuticals, 1997.
- 37 Dan WR, Kevin LF, June FM, Karen MA, Todd DH, Michael GM; *Pharmaceutical technology*, (2002) 48-54.
- 38 Joan R, Peter T, Ruben L, Pankaj S; *American pharmaceutical review*.
- 39 Espinosa Bosch M, Ruiz Sanchez AJ, Sanchez Rojas F, Bosch Ojeda C; *Journal of pharmaceutical and biomedical analysis*, 46, (2008) 9-17.
- 40 Caner H, Groner E, Levy L; *Drug discovery today*, 9, (2004) 105-110.
- 41 Caldwell J.; *Journal of chromatography A*, 719, (1996) 3-13.
- 42 Hubbard JW, Ganes D, Lim HK, Midha KK; *Clinical biochemistry*, 19(2) (1986) 107-112.
- 43 Drayer DW; *Clinical pharmacology and therapeutics*, 40, (1986) 125.
- 44 Ariens EJ; *Medicinal research reviews*, 6, (1986) 451.
- 45 Kasawar GB, Farooqui M; *Journal of pharmaceutical and biomedical analysis*, 52, (2010) 19-29.
- 46 Day RA and Underwood AL., "Quantitative Analysis", 5th Edn, **Prentice Hall**, New Delhi, 1986.
- 47 Bassett J, Denney RC., Jeffery GH and Mendham J, "Vogel's text book of quantitative Inorganic analysis", 4th Edn, **Longman group**, England, 1986.
- 48 Ramana Rao G, Murty SSN and Khadgpathi P, "Gas chromatography to pharmaceutical analysis", (Review), **Eastern pharmacist**, 30 (353), (1987) 35,

References

- 49 Ramana Rao G, Murty SSN and Khadgapathi P, “High performance Liquid chromatography and its role in pharmaceutical analysis” (Review), *Eastern Pharmacist*, , 29 (346), (1986) 53.
- 50 Sastry CSP, Prasad TNV and Rao EV, “Recent applications of High performance liquid chromatography in pharmaceutical analysis” (Review)., *Indian J. Pharm. Education*, 21, (1987) 37.
- 51 Macek, Karel., “Pharmaceutical applications of Thin Layer and paper chromatography”., *Elsevier publishing company*, Amsterdam, 1972.
- 52 Gorog S, Brlik J, Csehi A, Halmos Z, Herenyi B, and Horvath P, “*Anal. Method. Instrum*”., 2, (1995)154.
- 53 Cunnif P, Edt., “Official Methods of Analysis Of AOAC International”., 16th Edn,1.*AOAC International*, Arlington, 1995.
- 54 Ahuja S, “Impurities Evaluation of Pharmaceuticals”., *Marcel Dekker*, New York, 1998.
- 55 Husain S, Rao RN, “*Monitoring of process impurities in drugs*”., 834, 1998.
- 56 Altria KD, “*J.Chromatogr*”., 735, (1996) 43.
- 57 “*CDER Guideline on Validation of Chromatographic Methods*”, US Food and Drug Administration, Center for Drugs and Biologics, Department of Health and Human Sciences,1994.
- 58 ICH, Q2A: “*Validation of Analytical Methods, Definitions and Terminology*”., 1994.
- 59 ICH, Q2B: “*Analytical Validation Methodology*”.,1996.
- 60 Williard. HH, Meritt LL Jr, Dean. JA and Settle FA Jr., “Instrumental methods of analysis”., 6th Edn, *CBS publishers*, New Delhi, 1986.
- 61 Elder DP, Lipczynski AM, A. Teasdale.; *Journal of pharmaceutical and biomedical analysis*, 48, (2008) 497-507.
- 62 Liu DQ, Sun M, Kord AS; *Journal of pharmaceutical and biomedical analysis*, 51(5), (2010) 999-1014.
- 63 *Elde DPr, Snodin D, Teasdale A; Journal of pharmaceutical and biomedical analysis*, 54(5), (2011) 900-10.

References

- 64 Jouyban A, Kenndler E; *Electrophoresis*, 29,(2008) 3531-3551.
- 65 Knox JH; *High performance liquid chromatography*, university press, 1978.
- 66 Simpson CF; *Practical performance liquid chromatography*, 1976.
- 67 Metha, Akul; "Derivation of Beer-Lambert Law"- *Pharma Xchange. Info.*, 2012.
- 68 Metha, Akul; *Pharma Xchange. Info.*, 2012.
- 69 FDA guidance for industry (2000)-analytical procedures and method validation, chemistry, manufacturing, and controls documentation, center for drug evaluation and research and center for biologics evaluation and research.
- 70 Korany MA, Mahgoub H, Ossama TF, Hadir MM; *Journal of advanced research*,3, (2012) 53-63.
- 71 Ferrarini A, Huidobro AL, Pellati F, Barbas C; *Journal of pharmaceutical and biomedical analysis*, 53, (2010) 122-129.
- 72 Collier JW, Shah RB, Bryant AR, Habib MJ, Khan MA, Faustino PJ; *Journal of pharmaceutical and biomedical analysis*, 54, (2011) 433-438.
- 73 Singh S, Bakshi M; *Pharmaceutical technology*, 24, (2000) 1-14.
- 74 Swartz ME, Jone MD, Fowler P, Andrew MA; *LC-GC N. Am*,75, (2002) 49-50.
- 75 Synder LR, Kirkland JJ, Glajach JLX; *In practical HPLC methods development*, John Wiley, New York, 295, (1997) 643-712.
- 76 Swartz M, Murphy MB; *Am Lab*, 37, (2005) 22-27.
- 77 Debebe Z, Nekhai S, Ashenafi M, David BL, Kalinowski DS, Victor RG, Byrnes WM, Richardson DR, Karla PK; *Journal of chromatography B*, 906, (2012) 25-32.
- 78 Qiang Fu, Shou M, Chien D, Markovich R, AM. Rustum AM; *Journal of pharmaceutical and biomedical analysis*, 51, (2010) 617-625.
- 79 Nguyen AT, Aerts T, Dam DW, Deyn PPD; *Journal of chromatography B*, 878, (2010) 3003-3014.
- 80 Deng S, Brett JW, Jensen CJ, Basar S, J. Westendorf J; *Food chemistry*,116,(2009) 505-508.
- 81 Formica Jra RN, Lorberb KM, Friedmanb AL, Biaa MJ, Lakkisa F, Smitha JD,

References

- Lorber MI "The evolving experience using everolimus in clinical transplantation". *Elsevier* March 36 (2),(2004) S495–S499.
- 82 Kumar A and Vidya Sagar J, LC and LC/MS approach for quantification of everolimus and its degradants and application in stress analysis, *Journal of Pharmacy Research*, 8(2), (2014) 152-161.
- 83 Salm P, Taylor PJ, Lynch SV, Pillans PI, Quantification and stability of everolimus (SDZ RAD) in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry, *J Chromatogr B Analyt Technol Biomed Life Sci*. Jun 5; 772(2), (2002) 283-290.
- 84 Mustafa Karapirli, Kizilgun M, Yesilyurt O, Gul H, Simultaneous determination of Cyclosporine A, Tacrolimus, Sirolimus, and Everolimus in Whole-Blood Samples by LC-MS/MS, *The Scientific World Journal*, Volume 2012; (2012) Article ID 571201: 8.
- 85 Sara Baldelli, Zenoni S, Merlini S, Perico N, Cattaneo D, Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection, *Clinica Chimica Acta*, 364(1–2), (2006) 354–358.
- 86 Khoschsorur Gholam Ali, (Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Austria), Simultaneous Measurement of Sirolimus and Everolimus in Whole Blood by HPLC with Ultraviolet Detection, *Clinical Chemistry*, 51 (9): (2005) 1721-1724.
- 87 Sara Baldelli, Murgia S, Merlini S, Zenoni S, High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus, *Journal of Chromatography B*, 816 (1–2), (2005) 99–105.
- 88 Kamberi Marika, Katherine F, Jianmin L, A Sensitive High-Throughput HPLC Assay for Simultaneous Determination of Everolimus and Clobetasol Propionate, *Journal of Chromatographic Science*, 46 , (2008).
- 89 Khoschsorur Gholam Ali, Fruehwirth F, Zelzer S, Stettin M, Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation, *Clinica Chimica Acta* ,380(1-2) (2007) 217-21.
- 90 Mc Millin GA, Johnson Davis K, Dasgupta A, Analytical performance of a LC-

References

- LC/MS Method for determination of everolimus concentrations in whole blood, *Ther Drug Monit*, 34 (2),(2012) 222-6.
- 91 Morgan PE, Brown NW, Tredger TM, A direct method for the measurement of Everolimus and Sirolimus in whole blood by LC-MS/MS using an isotopic everolimus internal standard, *Ther Drug Monit* 36 (3),(2014) 358-65.
- 92 Kamberi M, Tran TN, UV-Visible spectroscopy as an alternative to liquid chromatography for determination of everolimus in surfactant containing dissolution Media, 70,(2012) 94-100.
- 93 Armin Buchwald, Karl Winkler, Thomas Epting, Validation of an LC-MS/MS Method to determine five immune suppressants with deuterated internal standards Including yMPA, *BMC clinical pharmacology*, 12 (2), (2012) 1472-6904.
- 94 Chao Yuan, Drew Payto, Jessica Gabler, Sihe Wang, A simple and robust LC-MS/MS method for measuring Sirolimus and everolimus in whole blood, *Bio analysis*, 6 (12), (2014) 1597-1604.
- 95 Magdalena Korecka, Sandra G Solari, Leslie M Shah, HPLC-MS/MS method with Online sample clean-up for everolimus measurement, *Therapeutic Drug Monitoring*, 28 (4), (2006) 484-90.
- 96 Taylor Paul J, Franklin Michael E, Graham Kendon S, Pillans Peter I, A HPLC-Mass Spectrometric method suitable for the therapeutic drug monitoring of everolimus, *Analytical technologies in the biomedical and life sciences*, 848 (2), (2007) 208-1214.
- 97 Vivek Upadhyay, Trivedi V, Shah PA, Shah JV, Liquid-liquid Extraction of Everolimus an Immuno suppressant from Human Whole Blood and its Sensitive Determination by UPLC-MS/MS, *J. of Advancement in Medical and Life Sciences*, 1(3), (2014).
- 98 Plumb,A Jane; Finn,W Paul; Williams,J Robert; Bandara,J Morwenna; Romero, M Rosario; Watkins,J Claire;LaThangue,BNicholas; Brown, Robert, *Molecular Cancer Therapeutics*, 2(8), (2003) 721-728: PMID 12939461.

References

- 99 Daniel Chan, Yun Zheng, Jeffrey W.Tyner, Wee Joo Chng, Wen Wen Chien, Sigal Gery, Geraldine Leong, Glenn D.Braunstein, H.Phillip Koeffler, *Journal of Cancer Research and Clinical Oncology*, 139 (9)(2013) 1507-1514.
- 100 Ling-Zhi Wang, Jacqueline Ramirez, Winnie Yeo, Mei-Yi Michelle Chan, Win-Lwin Thuya, Jie-Ying Amelia Lau, Seow.Ching Wan, Andrea Li-Ann Wong, Ying-Kiat Zee, Robert Lim, Soo-Chin Lee, Paul C.Ho, How-Sung Lee, Boon-Cher Goh, *Journal. Pone.* 0054522: (2013) 10.1371.
- 101 Jimeno A, J Dermott Mc, *Drugs today*, 50(5),(2014) 337.
- 102 Anish Thomas, Arun Rajan, Sean Khozin, Eva Szabo, Corey Allan Carter, Udayan Guha, Michell Manu, Arlene W Berman, Tricia Kunst, Richard, Piekarz, S David, Schrump, Giuseppe Giaccone, *Journal of Oncology*, 30(15),(2012) 7103.
- 103 Brian F Kiesel, Robert A Parise, Jette Tjornelund, Mette K Christensen, Einars Loza, Hussein Tawbi, Edward Chu, Shivaani Kummar, Jan H Beumer, *Journal of Pharmaceutical and Biomedical Analysis*,81-82, (2013) 89-98.
- 104 Ling-Zhi Wang, Daniel Chan, Winnie Yeo, Seow-Ching Wan, Stephen Chan, Anthony Chan, Soo-Chin Lee, How-Sung Lee, Boon-Cher Goh, *Journal of Chromatography B*, 878(26) (2010) 2409-2414.
- 105 Katherine E. Warren, Cindy Mc Cully, Henrik Dvinge, Jette Tjornelund, Maxwell Sehested, Henri S. Lichenstein, Frank M. Balis, *Cancer Chemother Pharmacol*, 62, (2007) 433-437.
- 106 Jasmine M Zain MD, Francine M Foss MD, Catherine S Diefenbach MD, Daniel Petrylak MD, Ameet Narwal, Ellen Neylon,NP,RN,BSN,OCN, Poul Knoblauch, Owen A.O'Connor MD, *Blood-American Society of Hematology*,118 (2011) 3710.
- 107 Jurate Savickiene, Grazina Treigyte, Giedre Valiulienė, Leva Stirblyte, Ruta Nava Kauskiene, Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone de-Acetylase inhibitor Belinostat in human acute promyelocytic leukemia cells, *Anti Cancer Drugs*, 25 (8), (2014) 938-49.

References

- 108 Naveen Kumar Ch, Prathyusha V, Kannappan N, A novel validated stability indicating RP-HPLC method development for the estimation of Ceritinib in its bulk and finished dosage form as per ICH guidelines, *Der Pharmacia Lettre*, 6(5), (2014) 339-351.
- 109 Olivier Heudi, Denise Vogel, Yvonne Y.Lau, Franck Picard, Olivier Kretz, Liquid chromatography tandem mass spectrometry method for the quantitative analysis of Ceritinib in human plasma and its application to pharmacokinetic studies, *Analytical Bioanalytical Chemistry*,; 406(28), (2014)7389-7396.
- 110 Alice T.Shaw, Dong-Wan Kim, Raneeh Mehra, Daniel S.W.Tan, Enriqueta Felib, Laura Q.M.Chow, D.Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Ceritinib has been approved in the US under 'Break through Therapy' designation for the second line treatment of ALK-positive non-small cell lung cancer (NSCLC), *The New England Journal of Medicine*, 370, (2014) 1189-1197.
- 111 Christian Lanshoeft, Olivier Heudi, Marc Raccuglia, Luc Alexis Leuthold, Franck Picard, Olivier Kretz, An ultrafast, sensitive, selective and robust LDTD-APCI-MS/MS method for the quantification of Ceritinib in human plasma, *Future Science –an impact of fsg*, 7(4) ,(2014) 425-435.
- 112 Nigel J.Waters, In vitro and in vivo assays, Ceritinib inhibited auto phosphorylation of ALK, ALK-dependent cancer cells, *British Journal of Clinical Pharmacology*: doi 10.1111/bcp. (2014) 12563.
- 113 Erminia Massarelli, Vassiliki Papadimitrakopoulou, Ceritinib-used for the treatment of late-age (metastatic) non-small cell cancer, *Clinical Cancer Research*, doi: 0.1158/1078-0432 (2015)CCR-14-1291.
- 114 Peng Wang, Jin Cai, Junqing Chen, Minji, Synthesis and anticancer activities of Ceritinib analogs modified in the terminal piperidine ring, *European Journal of Medicinal Chemistry*, 93,(2015) 1-8.
- 115 Agarwal, R. The first approved agent in the Glitazar's Class Saroglitazar. *PubMed.gov*, ,5(2), (2014)151-155.
- 116 Rajendra, H., Jani, Kevinkumar, K. M. R., Jain, & Harilal Patel Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a predominantly PPAR α Agonist with Moderate PPAR γ Agonist Activity in

References

- Healthy Human Subjects. *Clinical Drug Investigation*, 33, (2013) 809–816.
- 117 Robert, R.H., Michael, A.L., Sunder, M., et al. Effects of the dual peroxisome proliferator- activated receptor- α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes. *Lancet*, 374, (2009) 126–35.
- 118 Fievet C., Fruchart, J., & Staels, B. PPAR α and PPAR γ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. *Current Opinion in Pharmacology*, 6(6), (2006) 606–614.
- 119 Ekta H Amin,, Dr.Dilip. G., & Maheshwari. Development and Validation of UV Spectrophotometric Method for Saroglitazar Tablets. *JPSBR*, 4(5), (2014) 312-315.
- 120 Siddhartha B & Sudheer Babu I. Method development and validation for the estimation of Saroglitazar in bulk and pharmaceutical in bulk and pharmaceutical dosage form by RP-HPLC. *World Journal of Pharmacy and Pharmaceutical Sciences*, 3(9), (2014) 567-575.
- 121 Siddhartha B & Sudheer Babu I, Method development and method validation of Saroglitazar in bulk and pharmaceutical dosage form by UV-Spectrophotometric method, *Inventi Rapid-Pharm Analysis and Quality Assurance*, 2014.
- 122 Lepist EI, Phan TK, Roy A, Tong L, MacLennan K, Murray B, Ray AS; Cobicistat Boosts The intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro, *Antimicrobial Agents and Chemotherapy*, **56** (10), (2012).
- 123 Highleyman L, Elvitegravir “Quad” single-tablet regimen shows continued HIV suppression 48 weeks, *HIV and Hepatitis.com*.
- 124 Elion R, Gathe J, Rashbaum B, and others. The Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/TenofovirDisoproxilFumarate(EVG/COBI /FTC/ TDF; Quad) Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). Boston, September (2010) 12–15 .

References

- 125 International Conference on Harmonization (ICH) Harmonised Tripartite Validation of Analytical Procedures: Text and Methodology, Q2 (R1), (2005).
- 126 Urooj Fatima, T. Mamatha, Gajula Rajesh Goud; *Der Pharmacia Sinica, Pelagia Research Library*, 5(5), (2014) 99-105.
- 127 Raghu Ram Jampala, V. Kiran Kumar, Nemala Appala Raju; *Pharmaceutical Methods*, 5(1), (2014) 7-13.
- 128 Kavitha K, Geetha Y, Hari Prasad G, Venkatnarayana R, Subramanian R; *Academic Journal Pharmacie Globale*, 4 (1), (2013) 1-5.
- 129 Deeks ED, *Adis, Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection*, *Pub Med.gov*, 74(2), (2014) 195-206.
- 130 Chandni Saha, Nazeeruddin Ahmed Md, *Development and validation of a simple UV spectrophotometric method for the determination of Cobicistat in its bulk form*, *Indo American Journal of Pharmaceutical Research*, 5(1), (2014) 7-13.
- 131 Raveendrababu VV, Pankaj K Sharma, Singhvi I, *A new gradient LC method for simultaneous estimation of Tenofovir Disoproxil fumarate, Cobicistat, Emtricitabine and Elvitegravir in bulk and tablet dosage form*, *Asian Journal of Chemistry*, 26(18), (2014) 6233-6237.
- 132 Shiny Ganji, Satyavati D, *Development and validation of RP-HPLC method for the analysis of Cobicistat and related impurities in bulk and pharmaceutical dosage forms*, *Asian Journal of Pharmaceutical Analysis*, V(1), (2015) 1-8.
- 133 Raghuram J, Kiran Kumar V, Appala Raju N, *Development and application of LC method for simultaneous determination of ELT, Tenofovir disoproxil fumarate, Emtricitabine and Cobicistat in fixed dosage form*, *Pharmaceutical methods*, 5(1), (2014) 7-13.
- 134 Nageswara Rao R, Guru Prasad K, Sravan Kumar KV, Ramesh B, *Analytical methods*, 5, (2013) 6693-6699.
- 135 Ravindrababu VV, Pankaj K. Sharma, Singhvi I, *Asian J. of Chemistry*, 26(18), (2014) 6233-6237.

References

- 136 Swetha P, Rajendra Prasad VVS, Bhagavan Raju M, Suresh Kumar N, Indo American J. of Pharmaceutical Research, 3(6), (2013) 4697-4705.
- 137 Parthi Swati S, Aher Kiran B, Bhavar Girija B et al., Recent research on analytical methods of analysis of Raltegravir and ELT: A review, International J. of Pharma Sciences, 6(2),(2015) 369-373.
- 138 Aouri M, Calmy A, Hirschel B et al., A validated assay by liquid chromatography- tandem mass spectrometry for the simultaneous quantification of ELT and rilpivirine in HIV positive patients, J. of Mass Spectrum, 48(5), (2013) 616-625.
- 139 Aditya, Dande Payal R, Deshpande Shirish, Nageswara Rao R, Analytical and Bioanalytical Techniques, 5(4), (2014) 146.
- 140 Purnachandra Rao P, Mogili Reddy D, Ramachandran D, World J. of pharmaceutical science, 2(12), (2014) 1822-1829.
- 141 Djerada Zoubir, Feliu Catherine, Tournois Claire, Vautier Damien, Binet Laurent, Robinet Arnaud, Marty Helene, Gozalo Claire, Lamiable Denis, Millart Herve, Validation of a fast method for quantitative analysis of ELT, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other anti retro viral agents in human plasma samples with a new UPLC-MS/MS technology, Journal of pharmaceutical and biomedical analysis,86, (2013) 100-11.
- 142 Azvolinsky, Ph.D., Anna, FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia; Cancer Network, 2014.
- 143 Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al., Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase; Chem Med Chem.,2 (1), (2007) 58–61.
- 144 Honigberg L, Verner E, Pan Z, Inhibitors of Bruton's Tyrosine Kinase, 2009.
- 145 Veeraraghavan S, Viswanadha S, Thappali S, Govindarajulu B, Vakkalanka S, Rangasamy M, Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study; J Pharm Biomed Anal, 107, (2015)151-158.
- 146 Sridhar Veeraraghavan, Srikant Viswanadha, Satish Thappali, Babu Govindarajulu, Swaroopkumar Vakkalanka, Manivannan Rangasamy,

References

- Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study; *Journal of Pharmaceutical and Biomedical Analysis*, 2014.
- 147 Sateesh Thappali, C.Wali Deepa, J.Bariwal, S.Kadams, S.R.Dhaneshwar, Simultaneous spectrophotometric estimation of ibuprofen and methocarbamol in tablet dosage form; *Indian Journal of Pharmaceutical Sciences*, 66, (2004) 810-813.
- 148 Andersson KE, Mulhall JP, Wyllie MG, Dapoxetine hydrochloride is used for the treatment of premature ejaculation, *BJU International*,97(2), (2006) 311-315.
- 149 Rajendra B Patil, Tushar A Deshmukh, Vijay R Patil, Stability indicating HPLC method for Dapoxetine hydrochloride in bulk and in formulation, *Int. J. of Pharmaceutical Sciences*, 6(5),(2014) 687-690.
- 150 Mehta P, Sahoo U, Seth AK , Development and validation of a RP-HPLC method for the determination of DAP in pharmaceutical dosage form, *Int. J. of pharmaceutical sciences review and research*, 6(2),(2011) 76-82.
- 151 Madhuri Sandhya M, Sathyaraj A, Suseela Lanka, Development and validation of RP-HPLC method for the estimation of DAP in tablet forms, *International Journal of Pharmaceutical Sciences Review and Research*, 14 (1) (2012).
- 152 Abirami G, Vetrichelvan T, Madan Mohan M, Development and validation of UV spectroscopy method for the determination of DAP in pharmaceutical formulation, *Int. J. of pharmaceutical development and technology*,4, (2014) 86-89.
- 153 Abirami G, Ananda Kumar K, Velmurugan R , Development and validation of UV spectroscopy method for the determination of DAP in pharmaceutical formulation, *J. of pharmacy research*,5(4),(2012) 1949-1951.
- 154 Kai Bin Liew, Kok Khiang Peh , Stability indicating HPLC-UV method for determination of DAP in pharmaceutical product, *Acta Poloniae Pharmaceutica-drug research*, 71(3), (2014) 393-400.

References

- 155 Kanani VV, Murali krishna KS. Development and validation of UV Spectrophotometric method for estimation of Dapoxetine HCL in bulk and dosage Form. *Int J Drug Dev & Res*, 5(1), (2013)161-167.
- 156 Nataraj KS, Reddy KK, Kumar DK, Kumar SS. Simple validated UV spectrophotometric method estimation of Dapoxetine. *J Chem PharmSci*,4(3), (2011)105-107.
- 157 Rohith T, Ananda S, A validated chiral liquid chromatographic method for the enantiomeric separation of DAP, *Int. J. of advanced research in pharmaceutical and biosciences*, 2(3), (2012) 311-319.
- 158 Bharat Jhanwar, Badri Prakash Nagori, Sourabh Jain, Vipul Vyas, RP-HPLC method for estimation of DAP and Tadalafil Hydrochloride as API and in tablet dosage form, *American J. of Pharmtech Research*,3(3), (2013) 757-768.
- 159 Chirag S Rajpara, Jawed Akhtar, Amit Khandhar, Development and validation of stability indicating RP-HPLC method for estimation of Tadalafil and DAP in solid dosage form, *Pharma Tutor Pharmacy Infopedia*,(2014) ART-1387.
- 160 Raval Kashyap, Srinivasa U, Kalindi Badodaria, Development and validation of RP-HPLC method for simultaneous estimation of Avanafil and DAP in bulk and dosage form, *World J. of pharmacy and pharmaceutical sciences*, 3(7), (2014) 1697-1719.
- 161 Giri AD, Bhusari VK, Dhaneshwar SR, Validated HPLC method for simultaneous quantitation of Tadalafil and DAP in bulk drug and formulation, *Int. J. pharm pharm sci*, 4(2), (2012) 654-658.
- 162 Rajeshwari M, Chenthilnathan, Rama K, RP-HPLC method for simultaneous estimation of Tadalafil and DAP in combined pharmaceutical dosage forms, *Int. J. of pharmacy and biological sciences*,4(2), (2014) 72-82.
- 163 Albin PT, Haribabu Y, Sosamma Cicy Eapen, Kutty SV Kumar, Nithyamol P, Validated RP-HPLC method for simultaneous estimation of Sildenafil citrate and DAP in tablet dosage form, *The pharma innovation journal*,2, (2013) 41-45.
- 164 Chapla B, Amin G, Pandya A, Kakadiya J, Shah N, Simultaneous estimation and validation of Vardenafil and DAP in pharmaceutical formulation by TLC densitometric method, *Int. Research J. of pharmacy*,3, (2012) 480-483.

References

- 165 Pandya A, Amin G, Chapla B, Patel N, Kakadiya P, Development and validation of HPTLC for simultaneous estimation of Sildenafil and DAP, *Int. J. of pharmaceutical research and bioscience*,1, (2012) 236-246.
- 166 Chetan A Prajapati, Bhavik S Patel, Badmanaban R, Development and validation of HPTLC method for simultaneous estimation of Sildenafil citrate and DAP in combined dosage form, *Pharma Tutor*,2(10), (2014) 142-152.
- 167 Chabukswar AP, Kuchekar BS, Patil SL, Moon SA, Chate SG, Pagare BD. spectrophotometric simultaneous determination of Dapoxetine and Sildenafil in combined tablet dosage form by absorbance corrected method. *Der Pharma Chemica*, 4(4), (2012)1404-1407.
- 168 Chetan A Prajapati, Bhavik S Patel, Development and validation of spectrophotometric method for simultaneous determination of Sildenafil citrate and DAP in their combined dosage formulation, *Pharma Tutor*,2(11), (2014) 84-88.
- 169 Nirav B Savjiyani, Parula B Patel, Simultaneous estimation of Vardenafil Hydrochloride and DAP in combined pharmaceutical dosage form by spectrophotometry and RP-HPLC, *Indo American Journal of Pharmaceutical Research*, 3 (5), (2013)3652-3668.
- 170 Rohith T, Ananda S, Development and validation of HPLC method for the determination of process related impurities in DAP, *Int. J. of research in pharmacy and chemistry*, 3(1), (2013) 74-82.
- 171 Ayre A, Varpe D, Nayak R, Vasa N, *Advance Research in pharmaceuticals and biological-ARPB*, 1(2), (2011).
- 172 Pawale SS, Saley SP, Mundhada DP, Tilloo Sk, *International Journal of pharmaceutical and chemical sciences* , 1 (4), (2014) 2277 – 5005.
- 173 Mathieu Verbeken, Sultan Suleman, Bram Baert, Elie Vangheluwe, Sylvia Van Dorpe, Christian Burvenich, Luc Duchateau, Frans H Jansen, Bart De Spiegeleer – *Malaria Journal*, (2011) 1475 – 2875.
- 174 International Conference on Harmonization Draft revised guidance on impurities in new drug substances – *Federal Register*, 65 (140), (2000) 45085.

References

- 175 International Conference on Harmonization Draft revised guidance on impurities in new drug products – Federal Register, 65 (139), (2000) 44791.
- 176 International Conference on Harmonization impurities, Q3C – Guidelines for residual solvents, Q3C, Federal Register, 62 (247), (1997) 67377.
- 177 International Conference on Harmonization specifications, Q6A: Test procedures and acceptance criteria for new drug substances and new drug products chemical substances, 65 (146), (1999) 67488.
- 178 International Conference on Harmonization harmonized tripartite guideline, Impurities in new drug substances Q3A ®, 2002, 2.
- 179 International Conference on Harmonization guidelines, Q3A validation of analytical procedure: Methodology, 6, (11), (1996).
- 180 Buchi Reddy R; Mukkanti K; Srinivasulu P; Srinivas KSV, *Chromatographia*, 68 (3-4), (2008) 275 – 280.
- 181 An HM, Wang JC, *West China J Pharm Sci*, 06 (2006).
- 182 Pan YF, Zhang JB, Ding J, Wang TM, *Quilu Pharmaceutical Affairs*, (07) (2008).
- 183 Kawabata K, Samata N, Urasaki Y, Fukazawa I, Uchida N, Uchida E, Yasuhara H. *J. Chromatogr.* 852, (2007) 389-397.
- 184 Jia J, Nan F, Liang MZ, Yu Q, Qin YP, Xiang J, *China J Hospital Pharmacy*, 24 (2010).
- 185 Ding L, Li L, Ma P, *J Pharm Biomed Anal*, 43, (2007) 575-579.
- 186 Brian F Kiesel, Robert A Parise, Jette Tjornelund, Mette K Christensen, Einars Loza, Hussein Tawbi, Edward Chu, Shivaani Kummar, Jan H Beumer, *Journal of Pharmaceutical and Biomedical Analysis*, 81-82, (2013) 89-98.
- 187 Ling-Zhi Wang, Daniel Chan, Winnie Yeo, Seow-Ching Wan, Stephen Chan, Anthony Chan, Soo-Chin Lee, How-Sung Lee, Boon-Cher Goh, *Journal of Chromatography B*, 878(26), (2010) 2409-2414.
- 188 Katherine E. Warren, Cindy Mc Cully, Henrik Dvinge, Jette Tjornelund, Maxwell Sehested, Henri S. Lichenstein, Frank M. Balis, *Cancer Chemother Pharmacol*, 62, (2007) 433-437.

References

- 189 Jurate Savickiene, Grazina Treigyte, Giedre Valiuliene, Leva Stirblyte, Ruta Nava Kauskiene, Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone de-Acetylase inhibitor Belinostat in human acute promyelocytic leukemia cells, *Anti Cancer Drugs*, 25 (8)(2014) 938-49.
- 190 Naveen Kumar Ch, Prathyusha V, Kannappan N, A novel validated stability indicating RP-HPLC method development for the estimation of Ceritinib in its bulk and finished dosage form as per ICH guidelines, *Der Pharmacia Lettre*; 6(5) (2014) 339-351.
- 191 Olivier Heudi, Denise Vogel, Yvonne Y.Lau, Franck Picard, Olivier Kretz, Liquid chromatography tandem mass spectrometry method for the quantitative analysis of Ceritinib in human plasma and its application to pharmacokinetic studies, *Analytical Bioanalytical Chemistry*, 406(28), (2014)7389-7396.
- 192 Alice T.Shaw, Dong-Wan Kim, Raneeh Mehra, Daniel S.W.Tan, Enriqueta Felib, Laura Q.M.Chow, D.Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Ceritinib has been approved in the US under 'Break through Therapy' designation for the second line treatment of ALK-positive non-small cell lung cancer (NSCLC), *The New England Journal of Medicine*, 370, (2014) 1189-1197.
- 193 Christian Lanshoeft, Olivier Heudi, Marc Raccuglia, Luc Alexis Leuthold, Franck Picard, Olivier Kretz, An ultrafast, sensitive, selective and robust LDTD-APCI-MS/MS method for the quantification of Ceritinib in human plasma, *Future Science –an impact of fsg*, 7(4), (2014) 425-435.
- 194 Nigel J.Waters, In vitro and in vivo assays, Ceritinib inhibited auto phosphorylation of ALK, ALK-dependent cancer cells, *British Journal of Clinical Pharmacology*, (2014): doi 10.1111/bcp.12563.
- 195 Azvolinsky, Ph.D., Anna, FDA Approves Ibrutinib for Chronic Lymphocytic Leukemia; *Cancer Network*, (2014).
- 196 Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al., Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase; *Chem Med Chem*, 2 (1), (2007) 58–61.
- 197 Honigberg L, Verner E, Pan Z, *Inhibitors of Bruton's Tyrosine Kinase*, 2009.

References

- 198 Veeraraghavan S, Viswanadha S, Thappali S, Govindarajulu B, Vakkalanka S, Rangasamy M, Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study; J Pharm Biomed Anal. 107,(2015) 151-158.
- 199 Sridhar Veeraraghavan, Srikant Viswanadha, Satish Thappali, Babu Govindarajulu, Swaroopkumar Vakkalanka, Manivannan Rangasamy, Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study; Journal of Pharmaceutical and Biomedical Analysis, 2014.
- 200 Sateesh Thappali, C.Wali Deepa, J.Bariwal, S.Kadams, S.R.Dhaneshwar, Simultaneous spectrophotometric estimation of ibuprofen and methocarbamol in tablet dosage form; Indian Journal of Pharmaceutical Sciences, 66, (2004) 810-813.